Literature DB >> 26202406

The co-inhibitory pathway and cellular immune imbalance in the progress of HBV infection.

Jie Chen1, Lanlan Wang2, Yang Fu1, Yi Li1, Yangjuan Bai1, Limei Luo1, Yun Liao1.   

Abstract

OBJECTIVE: Chronic hepatitis B (CHB) affects 400 million people and is the most common cause of liver cirrhosis (LC) and hepatocellular carcinoma (HCC) worldwide. Cellular immune regulation plays an important role in determining the infection outcome. Co-signal molecules and Th17/Treg were studied to explore their association with the progression of HBV infection.
METHODS: Ninety-four HBV-infected patients were categorized into three groups: 31 patients with LC caused by CHB, 30 with HCC caused by CHB and 33 with HCC caused by CHB. Co-signal molecules, Th17/Treg, and Stat3 and Stat5 were analyzed by flow cytometry.
RESULTS: CHB patients who progressed to LC or HCC showed a significantly higher level of co-inhibitory molecules such as BTLA and PD-1, while there was no significant difference in co-stimulatory molecules among LC, HCC and CHB. Stat3 and Stat5 were significantly increased in LC and HCC compared to CHB patients.
CONCLUSION: Co-inhibitory molecules play more important roles than co-stimulatory molecules. Increased PD-1 and BTLA/HVEM inhibited immune cells and the immune process. At the same time activated Stat3 and Stat5 stimulate the key factors in differentiation of Th17 and Treg, thus leading to imbalanced expansion of Th17 and Treg; immune tolerance was induced and HBV persistent. This resulted in hepatic inflammation that progressed to cirrhosis and carcinoma.

Entities:  

Keywords:  BTLA; PD-1; Regulatory T cells; Stat; Th17

Year:  2013        PMID: 26202406     DOI: 10.1007/s12072-013-9464-x

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  23 in total

Review 1.  PD-1/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection.

Authors:  T Watanabe; A Bertoletti; T A Tanoto
Journal:  J Viral Hepat       Date:  2010-05-10       Impact factor: 3.728

2.  CD28 costimulation: walking the immunological tightrope.

Authors:  David M Sansom; Lucy S K Walker
Journal:  Eur J Immunol       Date:  2013-01       Impact factor: 5.532

3.  HVEM signalling at mucosal barriers provides host defence against pathogenic bacteria.

Authors:  Jr-Wen Shui; Alexandre Larange; Gisen Kim; Jose Luis Vela; Sonja Zahner; Hilde Cheroutre; Mitchell Kronenberg
Journal:  Nature       Date:  2012-08-09       Impact factor: 49.962

4.  Increased Th17 cells and interleukin-17 contribute to immune activation and disease aggravation in patients with chronic hepatitis B virus infection.

Authors:  Bo Yang; Yadong Wang; Caiyan Zhao; Wenzhao Yan; Honghao Che; Chuan Shen; Meng Zhao
Journal:  Immunol Lett       Date:  2012-12-10       Impact factor: 3.685

5.  Synergistic and additive effects of cimetidine and levamisole on cellular immune responses to hepatitis B virus DNA vaccine in mice.

Authors:  X Niu; Y Yang; J Wang
Journal:  Scand J Immunol       Date:  2013-02       Impact factor: 3.487

6.  Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis B.

Authors:  Ji Chen; Xiao-Mei Wang; Xue-Jie Wu; Yan Wang; Hong Zhao; Bing Shen; Gui-Qiang Wang
Journal:  Inflamm Res       Date:  2010-07-27       Impact factor: 4.575

Review 7.  HVEM: An unusual TNF receptor family member important for mucosal innate immune responses to microbes.

Authors:  Jr-Wen Shui; Mitchell Kronenberg
Journal:  Gut Microbes       Date:  2013-01-18

8.  Modulation of p38 MAPK signaling enhances dendritic cell activation of human CD4+ Th17 responses to ovarian tumor antigen.

Authors:  Martin J Cannon; Hannah E Goyne; Pamela J B Stone; Laura J Macdonald; Lindsey E James; Everardo Cobos; Maurizio Chiriva-Internati
Journal:  Cancer Immunol Immunother       Date:  2013-01-25       Impact factor: 6.968

9.  High antigen levels are the cause of T cell exhaustion during chronic viral infection.

Authors:  Scott N Mueller; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-11       Impact factor: 11.205

10.  Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B.

Authors:  Paola Fisicaro; Caterina Valdatta; Marco Massari; Elisabetta Loggi; Elisabetta Biasini; Luca Sacchelli; Maria Cristina Cavallo; Enrico M Silini; Pietro Andreone; Gabriele Missale; Carlo Ferrari
Journal:  Gastroenterology       Date:  2009-09-30       Impact factor: 22.682

View more
  3 in total

1.  Balance lost: T cell immunity in progressive HBV infection.

Authors:  Bertram Bengsch; Robert Thimme
Journal:  Hepatol Int       Date:  2014-01-09       Impact factor: 6.047

2.  Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection.

Authors:  Na Li; Zhihua Zhou; Fang Li; Jiao Sang; Qunying Han; Yi Lv; Wenxuan Zhao; Chunyan Li; Zhengwen Liu
Journal:  Oncotarget       Date:  2017-07-11

Review 3.  BTLA/HVEM Signaling: Milestones in Research and Role in Chronic Hepatitis B Virus Infection.

Authors:  Xueping Yu; Yijuan Zheng; Richeng Mao; Zhijun Su; Jiming Zhang
Journal:  Front Immunol       Date:  2019-03-29       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.